Observational studyHealth and quality of life outcomes2020
Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Observational study in Health and quality of life outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
Effects of Dance-based Multimodal Exercise Programme for Managing Chemotherapy-induced Peripheral Neuropathy in Patients With Solid Tumors: A Pilot Randomized Controlled Study
Who cites it
41 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Assessment measures for chemotherapy-induced peripheral neuropathy among pediatric oncology patients: an updated systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- BeyondFrontiers in pain research (Lausanne, Switzerland) · 2025Pooled it
- Peripheral Neuropathy Instruments for Individuals with Cancer: A COSMIN-Based Systematic Review of Measurement Properties.Current oncology (Toronto, Ont.) · 2024Pooled it
- The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies.Journal of cancer survivorship : research and practice · 2024Pooled it
- Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review.Frontiers in oncology · 2024Pooled it
- Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Pooled it
- Supportive care: Comparing exercise interventions for upper extremity polyneuropathy induced by chemo- or immunotherapy - VISCIPH B.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Evaluating the efficacy of photobiomodulation therapy in the management of chemotherapy-induced peripheral neuropathy: a pilot trial (NEUROLIGHT trial).Lasers in medical science · 2026Trial
- Trial
- Low-Intensity Vibration to Reduce Symptoms and Improve Physical Functioning in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Pilot Randomized Trial.JCO oncology practice · 2026Trial
- Trial
- Trial
- Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Sustained effects of auricular point acupressure on chemotherapy-induced neuropathy: a randomized controlled trial follow-up study.Journal of cancer survivorship : research and practice · 2026Article
- Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies.Journal of gynecologic oncology · 2026Article
- Assessment tools for chemotherapy-induced peripheral neuropathy: a narrative review of clinician, patient-reported, and objective measures.JNCI cancer spectrum · 2026Review
- Precision acupuncture for chemotherapy-induced peripheral neuropathy: multitarget mechanisms and integrated clinical translation framework.Frontiers in neurology · 2026Review
- Evaluation of the Efficacy and Safety of the Addition of Lacosamide to Duloxetine in the Treatment of Taxane-induced Peripheral Neuropathy: A Randomized Double-Blind Placebo-Controlled Trial.Journal of research in pharmacy practice · 2026Article
- Assumptions Used in Trial Sequential Analysis of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy [Letter].Journal of pain research · 2026Article
- Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.Blood advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe aim of this study was to evaluate the psychometric properties of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
methodsPatients were assessed with the FACT/GOG-Ntx subscale, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale 20 (EORTC QLQ-CIPN20), National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), and light touch test using 10 g monofilament for up to ten assessment points from baseline (prior to initiation of first chemotherapy), after the end of each cycle (up to 6 cycles, 3 weeks per cycle), and at 6, 9, and 12 months after starting chemotherapy. Psychometric analyses included internal consistency reliability, convergent validity, factorial validity, sensitivity to change and responsiveness (minimal clinically important difference, MCID).
resultsCronbach's alpha coefficients of the FACT/GOG-Ntx subscale were 0.82-0.89 across assessment points. The subscale strongly correlated with the EORTC QLQ-CIPN20 (r = 0.79-0.93) but low-to-moderately correlated with the NCI-CTCAE sensory (r
conclusionThe FACT/GOG-Ntx subscale has satisfactory reliability, validity, sensitivity to change and responsiveness to evaluate CIPN in cancer patients. Future research is needed to explore the factorial structure of the FACT/GOG-Ntx subscale as the published four-factor structure was not supported in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.